Background: Transcatheter aortic valve implantation (TAVI) has become an appealing treatment option in elderly pa-tients with aortic stenosis, especially in patients with increased surgical risk. Aim of Study: To report local expertise, clinical outcomes, and 6-month follow-up of patients undergoing TAVI. Patients and Methods: This study is retrospective and pro-spective, conducted from January 2022 to May 2023. It includ-ed 151 patients treated with TAVI. However, 29 patients were missed during follow-up, to complete the study with 122 pa-tients fulfilling the inclusion criteria. Results: The mean age was 73.67±7.04 years, 52.5% were females, and 59% were low riskaccording to Euro Score II. Three valve platforms were used and Evolut R was the most common (78.6%). Survival rate at 30-days was 97.5%, and 96.7% at 6-months. Incidence of stroke was 1.6% at 1-month, permanent pacemaker implantation 6.6%, no acute kidney in-jury, 2 patients experienced vascular complications (1.6%), and no patients had more than mild paravalvular leakage. Regard-ing symptomatology, there was ahighly significant improve-ment at the 6-month follow-up in which the majority of patients became at NYHA I (91.8%) and II (7.4%) (p<0.001). The Euro quality of life questionnaire was used and revealed significant improvement in general health status in all five dimensions with an overall Euro-quality of life visual analogue scale (EQ-VAS) score of 62.48±4.99 at baseline and 84.92±7.33 at follow-up (p<0.001). Conclusions: Our study demonstrated low rates of proce-dure-related complications, favorable short-term clinical out-comes, and a significant improvement in symptomatology and general health status.